Full text is available at the source.
The Cochrane database of systematic reviews··
Comparing talk therapy and medication for panic disorder with or without fear of open spaces in adults
Updated
Abstract
A total of 966 participants were included across 16 studies comparing psychological therapies and pharmacological interventions for panic disorder.
- No significant differences were found between psychological therapies and selective serotonin reuptake inhibitors (SSRIs) for short-term remission or response.
- There was also no difference in treatment acceptability, as measured by dropout rates, between psychological therapies and SSRIs.
- Similar findings were observed when comparing psychological therapies to tricyclic antidepressants, other antidepressants, and benzodiazepines for short-term outcomes.
- The quality of evidence was low to very low, leading to uncertainty about the efficacy and acceptability of each treatment modality.
- Sensitivity analyses suggested that factors like quality control of therapies and length of intervention could influence outcomes.
- No data were available for a comparison between psychological therapies and serotonin-norepinephrine reuptake inhibitors (SNRIs) or concerning adverse effects.
Simplified
BACKGROUND: Panic disorder is common and deleterious to mental well-being. Psychological therapies and pharmacological interventions are both used as treatments for panic disorder with and without agoraphobia. However, there are no up-to-date reviews on the comparative efficacy and acceptability of the two treatment modalities, and such a review is necessary for improved treatment planning for this disorder.
OBJECTIVES: To assess the efficacy and acceptability of psychological therapies versus pharmacological interventions for panic disorder, with or without agoraphobia, in adults.
SEARCH METHODS: We searched the Cochrane Common Mental Disorders Group Specialised Register on 11 September 2015. This register contains reports of relevant randomised controlled trials from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950 to present), Embase (1974 to present), and PsycINFO (1967 to present). We cross-checked reference lists of relevant papers and systematic reviews. We did not apply any restrictions on date, language, or publication status.
SELECTION CRITERIA: We included all randomised controlled trials comparing psychological therapies with pharmacological interventions for panic disorder with or without agoraphobia as diagnosed by operationalised criteria in adults.
DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and resolved any disagreements in consultation with a third review author. For dichotomous data, we calculated risk ratios (RR) with 95% confidence intervals (CI). We analysed continuous data using standardised mean differences (with 95% CI). We used the random-effects model throughout.
MAIN RESULTS: We included 16 studies with a total of 966 participants in the present review. Eight of the studies were conducted in Europe, four in the USA, two in the Middle East, and one in Southeast Asia.None of the studies reported long-term remission/response (long term being six months or longer from treatment commencement).There was no evidence of a difference between psychological therapies and selective serotonin reuptake inhibitors (SSRIs) in terms of short-term remission (RR 0.85, 95% CI 0.62 to 1.17; 6 studies; 334 participants) or short-term response (RR 0.97, 95% CI 0.51 to 1.86; 5 studies; 277 participants) (very low-quality evidence), and no evidence of a difference between psychological therapies and SSRIs in treatment acceptability as measured using dropouts for any reason (RR 1.33, 95% CI 0.80 to 2.22; 6 studies; 334 participants; low-quality evidence).There was no evidence of a difference between psychological therapies and tricyclic antidepressants in terms of short-term remission (RR 0.82, 95% CI 0.62 to 1.09; 3 studies; 229 participants), short-term response (RR 0.75, 95% CI 0.51 to 1.10; 4 studies; 270 participants), or dropouts for any reason (RR 0.83, 95% CI 0.53 to 1.30; 5 studies; 430 participants) (low-quality evidence).There was no evidence of a difference between psychological therapies and other antidepressants in terms of short-term remission (RR 0.90, 95% CI 0.48 to 1.67; 3 studies; 135 participants; very low-quality evidence) and evidence that psychological therapies did not significantly increase or decrease the short-term response over other antidepressants (RR 0.96, 95% CI 0.67 to 1.37; 3 studies; 128 participants) or dropouts for any reason (RR 1.55, 95% CI 0.91 to 2.65; 3 studies; 180 participants) (low-quality evidence).There was no evidence of a difference between psychological therapies and benzodiazepines in terms of short-term remission (RR 1.08, 95% CI 0.70 to 1.65; 3 studies; 95 participants), short-term response (RR 1.58, 95% CI 0.70 to 3.58; 2 studies; 69 participants), or dropouts for any reason (RR 1.12, 95% CI 0.54 to 2.36; 3 studies; 116 participants) (very low-quality evidence).There was no evidence of a difference between psychological therapies and either antidepressant alone or antidepressants plus benzodiazepines in terms of short-term remission (RR 0.86, 95% CI 0.71 to 1.05; 11 studies; 663 participants) and short-term response (RR 0.95, 95% CI 0.76 to 1.18; 12 studies; 800 participants) (low-quality evidence), and there was no evidence of a difference between psychological therapies and either antidepressants alone or antidepressants plus benzodiazepines in terms of treatment acceptability as measured by dropouts for any reason (RR 1.08, 95% CI 0.77 to 1.51; 13 studies; 909 participants; very low-quality evidence). The risk of selection bias and reporting bias was largely unclear. Preplanned subgroup and sensitivity analyses limited to trials with longer-term, quality-controlled, or individual psychological therapies suggested that antidepressants might be more effective than psychological therapies for some outcomes.There were no data to contribute to a comparison between psychological therapies and serotonin-norepinephrine reuptake inhibitors (SNRIs) and subsequent adverse effects.
AUTHORS' CONCLUSIONS: The evidence in this review was often imprecise. The superiority of either therapy over the other is uncertain due to the low and very low quality of the evidence with regard to short-term efficacy and treatment acceptability, and no data were available regarding adverse effects.The sensitivity analysis and investigation of the sources of heterogeneity indicated three possible influential factors: quality control of psychological therapies, the length of intervention, and the individual modality of psychological therapies.Future studies should examine the long-term effects after intervention or treatment continuation and should provide information on risk of bias, especially with regard to selection and reporting biases.
Related papers
Nov '23
Comparing drug treatments for panic disorder in adults
cited by 13 papers
systematic review
Mar '19
Benzodiazepines compared to placebo for panic disorder in adults
cited by 26 papers
systematic review
Apr '18
Antidepressants compared to placebo for treating panic disorder in adults
cited by 27 papers
systematic review
Jul '17
Vortioxetine treatment for depression in adults
cited by 21 papers
systematic review
Apr '16
Comparing psychological therapies for adults with panic disorder, with or without fear of open spaces
cited by 71 papers
systematic review
Jun '19
Antidepressants combined with benzodiazepines in adults with major depression
cited by 27 papers
systematic review
May '18
Psychological treatments for adults with depression that doesn't respond to usual care
cited by 53 papers
systematic review
Nov '14
Drug treatments for adults with somatoform disorders
cited by 92 papers
systematic review
May '19
How ongoing and long-term treatments compare for adults with lasting depression
cited by 28 papers
systematic review
Sep '16
Antidepressants and benzodiazepines for treating panic disorder in adults
cited by 15 papers
journal article